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INTRODUCTION
Osteoarthritis is a chronic disease of the joints that causes pa-
tients to suffer a progressive functional disability. This disease is 
not age-related, but once patent, it progresses with aging(1-3). It 
is related to a loss of joint functional ability, and is characterized 
by continuous pain. The lack of cure for osteoarthritis results in 
pain being the only issue treated by means of topical agents, 
anti-inflammatory agents, opioids and a-adrenergic analgesics, 
intra-articular agents, such as depocorticosteroids, hyaluronate 
and beta-irradiating radionucleotides, sulfated glycosamino-
glycans, such as the chondroitin sulfate (CS) and glucosamine 
sulfate (GS)(4-6). On the other hand, surgical treatment by means 
of debridements, osteotomies and total prosthesis have been 
providing good effects.
Glucosamine (N-acetyl-glucosamine) is a byproduct of the glucose 
metabolism and this degradation byproduct is one of the contents 
of the gallate and glycosaminoglycans(6). Glycosaminoglycans are 
linear polymers formed by repeated disaccaridic units where one of 
the units is invariably a hexosAmine (D-glucosamine or D-galactos-
amine) and the other is an hexuronic acid (glucuronic or iduronic) 
or a non-ramified sequenced galactose presenting replacements 
of sulfate groups in many positions of the polysaccharidic chain(7).
The three disaccharidic units: N-acetyl-galactosamine-hexuronic 
acid; N-acetyl-glucosamine-hexuronic acid, and N-acetyl-glu-
cosamine-galactose represent the basic units in the formation of 
glycosaminoglycans chain. The galactosaminoglycans, of which 
hexosamine will always be a D-galactosamine, are formed by the 
chondroitin sulfate family; and glycosaminoglycans, of which hex-
osamine will always be a D-glucosAmine, are formed by hyaluronic 
acid, heparan sulfate, heparin and cheratam sulfate.
In the category of chondroitins, we will find non-sulfated chondroi-
tins, 4-sulfated, 6-sulfated and the dermatan sulfate(1).
Chondroitin sulfates are formed by repeated disaccharidic units of 
glucoronic acid bonded by a N-acetyl-galactosamine, and present 
an ether sulfate at 4- or 6- position and for this reason the polysac-
charide formed is named chondroitin 4-sulfate or 6-sulfate.
Chondroitin sulfate chains vary in their average length from one 
tissue to another or within the same tissue. In general, the aver-
age molecular mass of the chondroitin sulfate chains in the joint 
cartilage is reduced with age (8). Except for hyaluronic acid, all 
glycosaminoglycans and/ or galactosaminoglycans are found 
as proteoglycans.
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SUMMARY
Osteoarthrosis is a chronic joint disease that, once patent, leads 
to a progressive functional disability. As proteochondroitin sul-
fates are the major contents of the cartilage, it is expected that 
the ingestion of glucosamine and chondroitin might improve the 
biological status of that tissue. As we could not find any studies 
on the pharmacokinetic profile of this association by oral admin-
istration route in human beings, the objective of this study was 
to evaluate it by using the association of glucosamine sulfate 
(GS) and chondroitin sulfate (CS) given to two groups of twelve 
healthy male volunteers (group I: one capsule containing 500 mg 
of GS and 400 mg of CS; group II: four capsules with the same 
content). Blood samples were collected at pre-determined time 
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intervals up to 48 hours post-dosing. GS and CS were measured 
in plasma by the DMMB (1,9,dimethyl-dimethilene blue) method. 
Maximum concentration was achieved within 2 hours (average ± 
SE; 0.893±0.093 g/ml, group I; and 2.222±0.313 g/ml, group 
II). Areas under curve up to 48 hours were 10.803±0.965 g-hr/
ml and 38.776±2.981 g-hr/ml for groups I and II, respectively. 
Both groups showed a second peak after 18 hours, indicating an 
enterohepatic flow. Our results indicate that this association is 
absorbed through the oral route by a saturable mechanism, which 
can enable its use in clinical treatments. 
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The kinds of proteoglycans in cartilage present with different 
hydrodynamic volumes, being this fact related to the number of 
glycosaminoglycan chains. It is important to remember that most 
of the glycosaminoglycans found in bones and cartilages are 
constituted by chondroitin sulfates.
Proteoglycans (PGs) are complex macromolecules containing 
a protein structure with one or more glycosaminoglycan chains 
covalently bonded(9-13). The protein structure of proteoglycans is 
centrally located in the molecule and is often supported by a “bed” 
formed by glycosaminoglycan chains.
In cartilages, the chondrocytes synthesize the various kinds of 
proteoglycans, which, together with the collagen matrix, form a 
supramolecular complex giving to this tissue a biological spring 
function, able to resist to high compressive forces, in addition of 
being involved in tissue growth and remodeling. Cartilages have 
a very high concentration of proteoglycans, which are respon-
sible for its morphological structure and for the nourishment of 
cartilaginous cells.
As proteochondroitin sulfates are the major contents of cartilage, 
it is expected that, by providing glucosamine and chondroitin, 
tissue’s biological conditions are improved. However, there are 
controversies surrounding the proposal of treatment benefits with 
glucosamine and chondroitin in patients with osteoarthritis(14-17).
The present study shows that the administration of glucosamine 
sulfate associated to chondroitin sulfate is orally absorbed by 
healthy individuals.
CASE SERIES, MATERIALS AND METHODS
Case Series
This protocol has been conducted according to the Declaration 
of Helsinki, described in the Resolutions 196/96 and 251/97 of the 
CNS/MS – Guidelines for Researches Involving Human Beings. 
The experimental protocol and the free and informed consent 
term (FICT) have been approved by the Committee of Ethics 
in Research at the Hospital do Rim e Hipertensão, certified by 
CONEP/Ministry of Health. Male healthy volunteers, with ages 
ranging 18-45 years old and body mass index (BMI) between 19 
and 25 have been included in the study. Individuals with clinically 
significant abnormalities in biochemical, blood and Urine I tests, 
presenting gastrointestinal, cardiovascular, hepatic, hematopoi-
etic, renal, or respiratory diseases, or with allergy history to CS and 
GS have been excluded from the study. Other exclusion criteria 
included: recent exposure (less 
than 3 months) to experimental 
or other drugs, recent intake or 
history of alcohol or illegal drugs 
abuse, smokers, recent blood 
donations (less than 3 months), 
HIV, Hepatitis B and C positive. 
The study was conducted at the 
Clinical Pharmacology Unit of the 
Hospital do Rim e Hipertensão, 
according to the rules of the 
Good Clinical Practices and the 
FICT was signed by all volunteers 
prior to the study.  
Study Design
This was an open-label, randomized, single-dose and single-
period study. Twenty four volunteers were randomly assigned 
to two groups of 12 individuals each. Group I (GI) received one 
500-mg capsule of CS and 400 mg of GS; Group II (GII) received 
four capsules. Volunteers were hospitalized the day before drug 
administration. Administration was provided at 7AM, after 10 hours 
of fasting. Volunteers remained seated during the four subsequent 
hours. Standardized meals were served within 4, 7, 11, 13, 24, 28, 
31, 35, 37, and 48 hours after drug administration.
Samples collection and handling
Blood samples of the volunteers in this study were collected before 
drug administration (baseline collection) and within 0.5, 1, 2, 4, 5, 
6, 8, 10, 12, 18, 24, 36, 48, and 168 hours in Vacuntainer® tubes,
totaling 15 aliquots. EDTA was used as anticoagulant. Samples 
were collected during the hospitalization period within 2 minutes 
of scheduled time, maintained in ice and centrifuged (10 minutes 
at 720 x g, 4ºC). Isolated plasma was frozen in two (2) aliquots 
and maintained at -20ºC until analysis. The time between blood 
collection and plasma freezing did not exceed 30 minutes.
Analytical method
The GS and the CS were dosed by the method using 1,9,di-
methyl-dimethylene blue(18) (DMMB), developed for determining 
sulfated glycosaminoglycans. The method, validated according to 
ANVISA’s guidelines, is based on the liquid-liquid extraction and 
spectrophotometry quantification. The method is linear between 
0.5 and 5.0 g/mL. Both GS and CS are stable in plasma within 
assay circumstances, at three cycles of freezing/unfreezing, to 
light, and up to three months of storage at –20ºC. The intra-as-
say accuracy ranges from 3.1 to 9.0% and inter-assay from 2.9 to 
13.9%; intra-assay accuracy ranges from 90 to 110% and inter-
assay, from 100 to 115%.  
Glucosamine and Chondroitin extraction
One milligram of papain dissolved in phosphate:cysteine buffer 
at a pH of 6.5 containing EDTA 0,10 M was added to each 2-ml 
aliquot of plasma sample. Samples were incubated at 55º C for 
16 hours. After incubation,  500 L of NaCL 4 M were added, and, 
after agitation, an amount equivalent to 10% of the total volume of 
90% trichloracetic acid (TCA). The supernatant was precipitated 
with absolute ethanol (3 times its volume) for 16 h at –20º C. The 
precipitate was vacuum-dried and re-suspended in 100 L of 
water. One milliliter of the DMMB reagent was added to the wa-
ter-diluted samples, followed by a careful agitation. Reading was 
performed in a spectrophotometer at 525 nm, within 3 minutes 
counting from the addition of DMMB. The standard curve was 
performed using the chondroitin 
sulfate (CS) solution (Aché Labo-
ratórios Farmacêuticos).
RESULTS AND 
DISCUSSION
Case Series
Anthropometrical data of the 
healthy volunteers participating 
in the study are summarized on 
Table 1. We can see that the study 
population is homogeneous and 
both groups are similar.  
Clinical Assay
The volunteers were observed during hospitalization and specifi-
cally inquired about adverse events at each 4 hours. During this 
period, no adverse event was observed. After 7 days of hospital 
discharging, volunteers were back for biochemical tests, ECG and 
clinical examination, when they were discharged from study.   
Plasmatic kinetics
Figure 1A shows the average ± SE of the gross results for both 
Table 1 - Anthropometrical data of the volunteers
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groups (including endog-
enous concentration). 
After oral administration, 
plasmatic concentration 
is increased, reaching 
maximum values after 2 
hours (Tmáx), decreasing 
at its minimum value after 
8 hours from intake, both 
for group I and group II. 
A second peak happens 
after 18 hours from in-
take, probably due to the 
enterohepatic re-flow(19).
Figure 1B shows the aver-
age ± SE of the net result, 
that is, after subtracting 
baseline concentration 
(endogenous).
The Cmax seen (above baseline 
concentration) was 0.893±  0.093 
g/mL and 2.222±0.313 g/mL
and the AUC0-48h 10.803±0.965 
g-h/mL and 28.543±6.704 g-
h/mL (average ±SE), respec-
tively for GI and GII. After 18 
hours from intake, concentration 
was 0.365±0.041 g/mL and 
0.974±0.198 g/mL, for GI and 
GII, respectively. Table 2 sum-
marizes the average ± SE of the 
computed parameters disregard-
ing the baseline plasmatic con-
centration (endogenous).
Absorption kinetics for 
CS and GS is not linear, 
as shown by the ratios 
between Cmax and AUC0-
48h (2.389 and 2.642, 
respectively, Table 2). 
This ratio is maintained in 
the 18-hour peak, result-
ing from enterohepatic 
re-flow (2.668), which 
reinforces the evidence 
that the absorption phase 
is limiting. Furthermore, 
half-life is also dosage-de-
pendent (16.931±1.902 h 
and  25.515±2.560 h, 
for 1 and 4 capsules, 
respectively).
CONCLUSION
Our results evidence that a single 
dose of up to four capsules of 500 
mg CS associated with 400 mg 
GS is well tolerated and the profile 
found is consistent to a 12-hour 
administration.
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Figure 1 - Plasmatic kinetics of the association of 400-mg glucosamine sulfate and 
500-mg chondroitin sulfate capsules. The points represent the average ± SE of twelve 
(12) volunteers. A, group I (1 capsule); B. group II (4 capsules).
Table 2 - Pharmacokinetic parameters calculated by subtracting 
baseline concentration (endogenous). Data represent the average 
± SE for each group. CS, chondroitin sulfate; GS, glucosamine 
sulfate. GI, group 1, one capsule administered; GII, group 2, four 
capsules administered.
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